Fang-Shu Ou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7787825/publications.pdf

Version: 2024-02-01

63 papers	3,212 citations	430874 18 h-index	161849 54 g-index
63 all docs	63 docs citations	63 times ranked	6059 citing authors

#	Article	IF	Citations
1	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 2022, 114, 427-435.	6.3	24
2	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 2022, 41, 260-267.	5.9	7
3	Diet- and Lifestyleâ€Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal of Clinical Oncology, 2022, 40, 740-751.	1.6	20
4	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Oncologist, 2022, 27, e494-e505.	3.7	5
5	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist, 2022, 27, 292-298.	3.7	2
6	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. Journal of Geriatric Oncology, 2022, 13, 469-479.	1.0	3
7	Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial.. Journal of Clinical Oncology, 2022, 40, 193-193.	1.6	4
8	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. JAMA Network Open, 2022, 5, e2149040.	5.9	48
9	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Network Open, 2022, 5, e220145.	5.9	3
10	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-Related Cancer, 2022, 29, 335-344.	3.1	8
11	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. Clinical Cancer Research, 2022, 28, 1690-1700.	7.0	7
12	Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). Epigenetics, 2022, , 1-11.	2.7	0
13	Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 3586-3586.	1.6	0
14	Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.. Journal of Clinical Oncology, 2022, 40, 3580-3580.	1.6	0
15	ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).. Journal of Clinical Oncology, 2022, 40, TPS4170-TPS4170.	1.6	0
16	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2022, 40, 3553-3553.	1.6	0
17	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
18	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2021, 27, 267-275.	7.0	13

#	Article	IF	Citations
19	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. Journal of Clinical Oncology, 2021, 39, 631-641.	1.6	63
20	The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Translational Oncology, 2021, 14, 100973.	3.7	8
21	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances, 2021, 5, 1737-1745.	5.2	4
22	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2021, 5, pkab034.	2.9	4
23	Biomarker Discovery and Validation: Statistical Considerations. Journal of Thoracic Oncology, 2021, 16, 537-545.	1.1	66
24	Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). European Journal of Cancer, 2021, 150, 214-223.	2.8	12
25	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	3.0	2
26	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	3.7	1
27	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer, 2021, 127, 3801-3808.	4.1	6
28	Randomized Phase II Study of PET Responseâ€“Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal of Clinical Oncology, 2021, 39, 2803-2815.	1.6	58
29	Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. Contemporary Clinical Trials Communications, 2021, 23, 100827.	1.1	0
30	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	2.9	22
31	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications, 2020, 17, 100492.	1.1	5
32	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	2.9	8
33	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 1713.	7.1	24
34	Guidelines for Statistical Reporting in Medical Journals. Journal of Thoracic Oncology, 2020, 15, 1722-1726.	1.1	10
35	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Network Open, 2020, 3, e2023500.	5.9	8
36	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1692-1695.	2.5	5

#	Article	IF	Citations
37	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
38	Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2020, 38, 4086-4086.	1.6	3
39	Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. Journal of Clinical Oncology, 2020, 38, 102-102.	1.6	1
40	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of Clinical Oncology, 2019, 37, 2620-2631.	1.6	51
41	Perioperative Gemcitabineâ€‰+â€‰Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology, 2019, 26, 4489-4497.	1.5	19
42	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1070-1082.	10.7	169
43	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2019, 25, 7497-7505.	7.0	44
44	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	1.8	4
45	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 2019, 37, 1876-1885.	1.6	169
46	Milestone prediction for timeâ€toâ€event endpoint monitoring in clinical trials. Pharmaceutical Statistics, 2019, 18, 433-446.	1.3	1
47	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. European Journal of Cancer, 2019, 111, 82-93.	2.8	17
48	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. Journal of Clinical Oncology, 2019, 37, 1217-1227.	1.6	234
49	Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. JCO Precision Oncology, 2019, 3, 1-10.	3.0	1
50	Marine omegaâ€3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	5.1	22
51	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patientâ€“Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology, 2018, 36, 2593-2602.	1.6	59
52	Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1227-1230.	2.5	15
53	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. Clinical Genitourinary Cancer, 2018, 16, e1117-e1122.	1.9	1
54	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	13.7	1,487

#	Article	IF	Citations
55	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. Journal of Clinical Oncology, 2018, 36, 3599-3599.	1.6	6
56	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 2018, 36, 612-612.	1.6	2
57	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer, 2017, 17, 505.	2.6	166
58	Primary (1Â°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2017, 35, 3503-3503.	1.6	49
59	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy Â± biologic: Findings from 9,092 pts in the ARCAD database.. Journal of Clinical Oncology, 2017, 35, 3535-3535.	1.6	6
60	Quantile regression models for current status data. Journal of Statistical Planning and Inference, 2016, 178, 112-127.	0.6	3
61	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. Blood, 2016, 128, 1102-1102.	1.4	3
62	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	1.4	5
63	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. Blood, 2016, 128, 4196-4196.	1.4	1